Desogestrel for preventing a premature luteinizing hormone (LH) surge in a cycle for oocyte cryopreservation
Objectives:The advance of cryopreservation techniques turn possible the use of new strategies for LH supression during in vitro fertilization (IVF) cycles. Methods: The use of progesterone instead of gonadotropin-releasing hormone (GnRH) analogues seems to be a feasible option. Desogestrel is a progesterone broadly known and accepted in the context of contraception, with a good tolerability and low cost, in addition to a potent anti-ovulatory potency. Results: The present case is the first describing a succesfully controlled ovarian hyperstimulation (COH) for social oocyte cryopreservation using desogestrel 75mcg as a LH blocker in a healthy 35-year-old woman. Conclusions: the use of progesterone for LH supression seems to be a great option in the context of oocyte cryopreservation, since it is safe, less expensive and patient-friendly, avoiding the daily injections of GnRH analogues.
1. Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104(1):62-70.e3. http://dx.doi.org/10.1016/j.fertnstert.2015.03.022. PMid:25956370.
2. Bosch E, Valencia I, Escudero E, Crespo J, Simón C, Remohí J, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril. 2003;80(6):1444-9. http://dx.doi.org/10.1016/j.fertnstert.2003.07.002. PMid:14667881.
3. Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, et al. Watanabe EMoriwaka O. New trial of progestin - primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298(3):663-71. http://dx.doi.org/10.1007/s00404-018-4856-8.
4. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe K, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7-16. http://dx.doi.org/10.1016/j.maturitas.2003.09.014. PMid:14670641.
5. Soules MR, Steiner RA, Clifton DK, Cohen NL, Aksel S, Bremner WJ. Progesterone modulation of pulsatile luteinizing hormone secretion in normal women. J Clin Endocrinol Metab. 1984;58(2):378-83. http://dx.doi.org/10.1210/jcem-58-2-378. PMid:6420438.
6. Milsom I, Korver T. Ovulation incidence with oral contraceptives: a literature review. J Fam Plann Reprod Health Care. 2008;34(4):237- 46. http://dx.doi.org/10.1783/147118908786000451. PMid:18854069.
7. Massin N. New stimulation regimens: Endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017;23(2):211-20. http://dx.doi.org/10.1093/humupd/dmw047. PMid:28062551.
8. Chen ZJ, Shi Y, Sun Y, Zhang B, Liang X, Cao Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2016;375(6):523-33. http://dx.doi.org/10.1056/NEJMoa1513873. PMid:27509101.
9. Wang Y, Kuang Y, Chen Q, Cai R. Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial. Trials. 2018;19(1):455. http://dx.doi.org/10.1186/s13063-018-2850-x. PMid:30134964.